Month: January 2022

Pro Medicus – Buy Zone

Posted on January 24, 2022 | by Leon Hinde

Pro Medicus is up 100% since the buy signal back in July 2020.

While the stock trades on a very high multiple 100x FY22 earnings, the 40%+ revenue and profit growth is supported by long-term contract wins. Watch for buying interest to build within the range indicated.

Inner Circle Investment Group

Posted on January 23, 2022 | by Leon Hinde

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

Inner Circle Investment Group

Posted on January 23, 2022 | by Leon Hinde

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

Woolworths – Accumulate

Posted on January 22, 2022 | by Leon Hinde

Woolworths Group announced a disappointing trading update which revealed COVID had weighed heavily on earnings during the first half. The retailer anticipates $215mil in COVID-related expenses and before tax profit to fall from $1.3bn to $1.2bn.

We see value in the stock within the highlighted price range.

ASX Signals for January 21, 2022

Posted on January 21, 2022 | by Algo Engine

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

Collins Foods – Buy Signal

Posted on January 21, 2022 | by Leon Hinde

Collins Foods is under Algo Engine buy conditions. Buying support is likely to increase within the highlighted price range.

Bega – Earnings Review

Posted on January 21, 2022 | by Leon Hinde

Bega recently provided a trading update, with FY22 underlying EBITDA expected to be in the range of
A$195-215mn.

Earnings have been impacted by supply chain-related disruptions, with some offset by the full-year contribution of the Lion Dairy & Drinks acquisition and related cost synergies. FY23 earnings should reaccelerate and recent shareholder support from Andrew Forrest suggests the current price range is a good opportunity to build a position.